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ABSTRACT 
Jacob S. Dunn: A Monte Carlo method to estimate radiation dose from cone beam computed 
tomography 
(Under the direction of John B. Ludlow) 
 
Objectives: This study compares effective dose determination of four large field of view 
CBCT units (NewTom-3G, Galileos Comfort Plus, CS-9300, iCat-FLX,) using a Monte Carlo 
software analysis method (PCXMC) and dosimetry using anthropomorphic phantoms.   
Methods: Previous research provided phantom effective dose comparisons.  Field-of-
view and phantom positioning were duplicated in the software.  Software and phantom 
dosimetry values were compared.  Descriptive statistics, chi-square, and logistic regression, 
were used to analyze the data.  The null-hypothesis that there is no statistically significant 
difference between the dosimetry values of the anthropomorphic phantom and the calculated 
values of the PCXMC software was tested.    
Results:  PCXMC simulated scans produced dose values within 20% of the phantom 
dosimetry 48-58% of the time. 
Conclusions: While the software calculations are simpler to perform than phantom 
dosimetry, imprecise calculated results make this program less effective for CBCT dosimetry in 
dentistry. 
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DEVELOPMENT OF MONTE CARLO 
 
“The first thoughts and attempts I made to practice [the Monte Carlo method] were 
suggested by a question which occurred to me in 1946 as I was convalescing from an 
illness and playing solitaires.  The question was what are the chances that a Canfield 
solitaire laid out with 52 cards will come out successfully?  After spending a lot of time 
trying to estimate them by pure combinatorial calculations, I wondered whether a 
more practical method than “abstract thinking” might not be to lay it out say one 
hundred times and simply observe and count the number of successful plays.  This 
was already possible to envisage with the beginning of the new era of fast computers, 
and I immediately thought of problems of neutron diffusion and other questions of 
mathematical physics, and more generally how to change processes described by 
certain differential equations into an equivalent form interpretable as a succession of 
random operations.”1 
 
 These remarks were made by Stanislaw Marcin Ulam, a Polish-American scientist who 
was one of the primary contributors in the development of the Monte Carlo method.  Born in 
1909 Lviv, in a Polish area of now Ukraine that was then part of the Austro-Hungarian Empire, 
Ulam studied mathematics throughout Europe until he was invited in 1935 to come to the 
Institute for Advanced Study in Princeton, New Jersey.2  This led to opportunities for  research 
at Harvard University in Cambridge, Massachusetts, until he became an assistant professor at 
the University of Wisconsin-Madison.2   
 In 1943, he was invited to join a special project near Santa Fe, New Mexico.  This top 
secret group was located at the Los Alamos National Laboratory, which research today is well 
known as the Manhattan Project.  His work ultimately led him to consider multiplicative 
systems and the statistics of branching.  These are situations in which particles interact with a 
system – with particulate type, number, position, momentum, and other intrinsic properties 
potentially changing with time.3  The branches – or individual steps of the process, utilized 
probability functions to determine the properties of the next generation of particles within the 
system.3  A group of other researchers, including Nicholas Metropolis and John von Neumann, 
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had been working out calculations on the first general electronic computer, called the Electronic 
Numerical Integrator and Computer (ENIAC).4   While Ulam was reviewing these calculations, 
he realized that the faster calculating ability of this machine would allow the reality of a method 
of statistical analysis he had considered while playing solitaire during a previous convalescence.1  
Von Neumann applied Ulam’s thought to a proposal to evaluate the behavior of neutrons during 
nuclear fission.5  Metropolis code named it “The Monte Carlo method” because Ulam had 
mentioned an uncle who frequented the Monte Carlo casinos.4  Together, they published an 
early, unclassified paper on the subject.6   
 
The Monte Carlo Method 
 The Monte Carlo (MC) method is a statistical approach to solving problems in systems in 
which there is a degree of uncertainty.  There are many methods to accomplish the task, but 
basic points include the following: the definition of the domain of possible inputs, the 
generation of random inputs based on probability actions within that domain, the computation 
of results (calculating a successful ‘hit’ or not, based on the definition of the domain), and finally 
an aggregation of the results.7  A simple example of this would be an attempt to calculate the 
value of π.  If a circle is circumscribed within a square and drawn on the floor, the ratio of the 
areas (circle to square) is π/4.  If many, many pins were dropped at random within the entirety 
of the square, and counted at the end, the number of points within the circle relative to the 
entirety of the square would also be very close to the fraction, π/4.7  This is one basic example of 
using the Monte Carlo method, including the inherent random sampling, to solve a 
mathematical problem.   
 This method is particularly suited to the evaluation of radiation transport in systems.8  
The simulation is performed by creating and following life histories of many photons.  Variables 
required for the photon evaluation include the photon position, the direction, the energy, and 
time.  Variables required for the interaction medium include geometry of the medium, location 
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of internal structures (organs) and characteristics of the organs (volume, shape, and 
attenuation).  The distribution of the photons utilize both measurements and theoretical 
properties of x-rays.7  Kalos and Whitlock effectively describe the steps involved: 
1. Pick a set of source variables (initial state of system). 
2. Follow the x-ray until it interacts with an atom. 
3. Determine whether the x-ray scatters 
 -if so, repeat from step 2; 
 -if not, terminate the history. 
Steps 2 and 3 are repeated until the x-ray photon is absorbed or is no longer capable 
of effecting the answer to any appreciable extent. 
4. Repeat the whole process from step 1 as many times as necessary to achieve the 
accuracy needed for the solution. 
5. Take arithmetic average of answers of all the histories.7 
 
 This sequence describing radiation transport in a system is essentially a “random walk” 
or a Markov chain, a process that has stepwise transitions involving randomness and 
probability.9, 10  Each step is a collision event, which outcome depends on the characteristics of 
the radiation and interaction medium.  Modeling of these collisions requires listing the possible 
events, then assigning the probability of each of those events occurring.  Just like with 
Hollywood actors, the life history of the photon is closely followed until interest in it is lost or it 
is terminated.7  Interest is lost when the photon is too low in energy to affect the answer, and 
termination occurs with a photoelectric effect or when it exits the system.  To summarize, the 
process simulates an x-ray photon with “random position, direction, and time, which travels in 
straight-line segments whose lengths are random; the photon interacts with the atoms 
constituting the medium at random, and its life history is concluded at random.”7 
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THE USE OF MONTE CARLO WITH DENTAL CBCT: REVIEW OF LITERATURE 
 
 A search for the term ‘monte carlo’ on PubMed yields nearly 40,000 results, illustrating 
the near ubiquity of this technique within medical physics, physical sciences, engineering, 
computer science, applied statistics, mathematics, artificial intelligence, image processing, 
biology, and even finance and business.11, 12    
 A review of the literature was completed on PubMed with the assistance of the School of 
Dentistry librarian.  The search used the terms “cone beam computed tomography AND 
dosimetry AND ‘monte carlo’”, and “cone beam computed tomography AND dosimetry AND 
‘monte carlo’ AND (dentistry OR dental)”, and “‘monte carlo’ AND (dentistry OR dental)”.   
 The majority of the articles involving cone beam computed tomography (CBCT) and 
Monte Carlo (MC) programs evaluate dose characteristics of the onboard CBCT as part of a 
linear accelerator used in image guided radiation therapy (IGRT).13-43  Additionally, dose 
evaluations of the associated electronic portal imaging devices are also common.16, 21, 44-46  Other 
studies involve dose evaluation of multi-detector computed tomography (MDCT),47-57 mega 
voltage CT,58-61 medical CBCT involving neurology,62 fluoroscopy,63 angiography,64 
mammography,65-67 and evaluation of internal radionuclides.68, 69  Of image quality interest are 
articles that evaluate CBCT scatter with the goal of image quality improvement through scatter 
reduction.70-72   
 
Monte Carlo Programs in Dentistry 
 A number of articles involving MC programs and dentistry pertain to the effect of dental 
restorations on doses within radiotherapy.73-77  Other articles evaluate the effect on absorbed 
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dose when adding rare earth filters,78 the electron paramagnetic resonance as a measure of dose 
within enamel,79 enamel beam hardening in micro CT,80 variations in light-induced fluorescence 
in enamel in the presence of caries,81 maxillofacial fluoroscopy82, and even estimates of caries in 
extended populations in Australia83.    
 Several studies use Monte Carlo methods to evaluate dose with dental plain film 
radiography.   Aps and co-workers investigated lateral radiographs and bitewing radiographs.84  
Batista and co-workers looked at the dose in panoramic images from conventional and CBCT 
machines.85  Lee and co-workers (2012) studied the effect of collimation in cephalography.86    
Nicopoulou-Karayianni and co-workers looked at radiation absorbed doses at titanium-bone 
interfaces in diagnostic dental radiography.87  Walker and co-workers proposed diagnostic 
references levels for intraoral and panoramic radiography.88 
 Dr. Julian Gibbs led several studies at Vanderbilt University involving Monte Carlo 
analysis and dental radiography.89-93  In 1982, Gibbs created a MC method to evaluate the dose 
distribution of an 80 kVp x-ray beam on a homogenous water phantom.  He found no significant 
differences between the estimated doses and the doses measured with an ionization chamber.  
In 1984, he used the same MC program to evaluate dose from molar interproximal radiographs 
on a voxel CT phantom of an adult female cadaver.  The voxels within the phantom were coded 
as air, lung, fat, muscle bone, or tooth, with attenuation factors coinciding with the then 
contemporary ICRP Reference Man recommendations.  X-rays were programmed to operate at 
90 kVp.  The sequence was run with a target-skin distance of 20 cm with round collimation, and 
40 cm with rectangular collimation.  Gibbs found that the use of long-cone technique with 
rectangular collimation would reduce the cancer risk by a factor of 2.9.90 
 In 1987, Gibbs and co-workers used the same MC program and same female cadaver 
phantom to evaluate the dose to sensitive organs during intraoral radiography.  The 
investigators found that organ doses generally increase with increasing beam energy.  Largest 
doses were found in organs near the primary beam.  In 1989, using the same MC program and 
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female cadaver phantom, Gibbs and co-workers simulated three radiographic examinations: 
chest, dental full mouth series, and dental panoramic.  The investigators found that collimated 
dental examinations, while being less homogenous than the chest examination, concentrated 
dose to organs of the head and neck.92   
 In 2000, Gibbs used the same MC program and cadaver phantom to evaluate additional 
radiographic protocols, including submentovertex (SMV), temporomandibular joint (TMJ), 
cephalometric, and a chest PA and lateral images.  Organ doses for each projection were 
determined at 70, 80, and 90 kVp.  Gibbs found that effective dose and effective dose equivalent 
calculations varied significantly between organs, depending on image protocol.93   
 
Monte Carlo Programs and Dental CBCT 
 Fully six articles deal with dosimetry using Monte Carlo methods on dental CBCT.94-99  In 
2010, Vassileva and co-workers used PCXMC (STUK, Helsinki, Finland) to estimate effective 
dose of the ILUMA Ultra CBCT (IMTEC Imaging, Ardmore, OK).  Software estimated effective 
doses were lower than those calculated with RANDO (The Phantom Laboratory, Salem, NY) 
phantom dosimetry by Ludlow and Ivanovic by over 68% with ICRP 103 recommendations.97, 100   
 In 2011, Zhang and co-workers evaluated the 3D Accuitomo 170 unit (J Morita, Japan), 
using the BEAMnrc/EGSnrc MC code system to simulate x-ray generation, filtration, and 
collimation.  Kerma free-in-air at the isocenter was validated by comparison against measured 
air kerma in water in a cylindrical water phantom.  Discrepancies between the two 
measurements varied less than 15%.98  In 2013, Zhang and co-workers investigated the 3D 
Accuitomo 170 and the Scanora 3D (Soredex, Finland).  The BEAMnrc/EGSnrc MC code was 
used again, on four phantoms: the two International Commission on Radiological Protection 
(ICRP) reference voxel phantoms (AM and AF), the Zubal phantom, which is another CT voxel 
phantom, and the VCH (Visible Chinese Human) phantom, which is based on axial photographs 
sections of a Chinese cadaver.  For the Accuitomo, FOVs included a 17x12 cm, 10x10 cm, and 6x6 
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cm.  For the Scanora, a 14.5x7.5 cm, 10x7.5 cm, and 6x6 cm FOV was included.  Absorbed organ 
dose and effective dose were calculated.  Of note is the fact that the thyroid was not part of the 
head/neck of any of the four phantoms, and as such, it was not included in the calculation of 
effective dose.99  The authors found that organ dose varied as much as 112% between phantoms, 
and that between the two machines examined, variation of organ doses between phantoms was 
greater than dose differences between machines.  Effective dose varied up to 30% (in terms of 
coefficient of variation, defined as the ratio of standard deviation to the mean, expressed as a 
percentage).  Differences in phantom anatomy were was surmised as the reasoning behind the 
difference in effective dose.   
 In 2012, Koivisto and co-workers evaluated effective dose on the Promax 3D CBCT 
(Planmeca, Helsinki, Finland) using new metal-oxide semiconductor field-effect transistors 
(MOSFET) dosimeter devices, and compared them with PCXMC estimated results.  The 
dosimeters were placed in a RANDO phantom according to protocol described by Ludlow and 
co-workers.101  The field of view (FOV) was 8x8cm, and positioned to capture the oral cavity 
volume.  The phantom scans and simulations were performed at various heights on the z-axis, to 
evaluate vertical positioning on effective dose.  Both the phantom and the simulation noted a 
distinct relationship between the presence of the thyroid within the scan, (and accordingly that 
organ’s equivalent dose) and total effective dose.  The difference between MOSFET measured 
and PCXMC estimated effective dose differed by as much as 52%, and differences in individual 
organ equivalent doses varied as much as 600%.102  Differences between the two were equated to 
differences in the mathematically modeled and physical phantom, regarding shape, volume, and 
positioning of the organs, particularly the thyroid.  Additionally, the authors noted that small 
differences in phantom head position had a substantial effect on effective dose.102   
 In 2012, Morant and co-workers evaluated the dose on an iCat next-generation CBCT 
(Imaging Sciences International, Hatfield, PA) using MC program Electron Gamma Shower V4 
(EGS4) (Stanford University, Palo Alto, CA) and compared the estimated results with ionization 
8 
chamber measurements and thermoluminescent dosimeters (TLD) in a water-filled Remab male 
adult phantom (Alderson Research Laboratory).  The imaging protocols examined were the 
“Landscape 13cm” and “Extended Field of View (Cephalometric, E-FOV)”.  Within the ionization 
chambers, percent difference between the two methods ranged up to 6%.  Within the phantom, 
relative differences between the organ dose values (mGy to air) ranged 1-84%, although more 
than half had less than 13% difference.  Statistical uncertainties of the MC program ranged 7-
19% for dose values ≥1 mGy, and increased to 100-130% for values of 0.01 mGy.95   
 Morant and co-workers again in 2013 studied MC program EGS4 simulated doses on the 
iCat next-generation CBCT.  The ICRP voxel adult male and female reference phantoms (AM 
and AF) were evaluated.  Nine different FOVs were simulated.  The authors found that organ 
and effective dose varied according to FOV, beam acquisition angles and positioning.  The full 
head scan (23 x 17cm FOV) estimated effective dose was 47% less than the results of Ludlow and 
Ivanovic, however, Davies and co-workers showed reasonable agreement with the other imaging 
protocols.100, 103   
 
PCXMC Studies in the Literature 
 A review of the literature was completed on PubMed with the search term “PCXMC.”      
Aside from the studies mentioned previously, the majority of studies involved radiography 
within the pediatric community.104-126  Other studies included fluoroscopy,127-133 angiography,134, 
135 other interventional radiography,136-139 tomosynthesis,140-143 and CBCT as a part of image 
guided radiation therapy.144-146  On the more technical side, studies investigated dose relating to 
structural shielding,147 source-to-image distance (SID),148, 149 dose-area-product (DAP),150 
collimation,151 different x-ray spectra,152 and projection angles.153, 154   
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BACKGROUND 
 
 Shortly after the initial discovery of x-rays by Wilhelm Roentgen, dentistry began 
incorporating radiology as a means of diagnosis.155  Through the years, the technology and use 
has kept pace with the increasing range and variation of treatment.  The utilization of radiology 
in dentistry was expanded with the development of commercial panoramic tomography in the 
early 1960s.156  The parallel development of cone beam computed tomography (CBCT), although 
nearly thirty years later, also allowed new avenues and diagnostic abilities.157   
 The use of CBCT imaging has significantly increased within general dentistry, 
endodontics, oral surgery, periodontics, and orthodontics.158-165  This increasing popularity of 
this technology is understandable with the ability of CBCT to reconstruct volumes, as well as 
present multi-planar simultaneous views, enabling the dental practitioner potentially much 
more information than previous two-dimensional radiography.  Responding to the demand 
within the field, there are currently many firms that manufacture CBCT machines, with multiple 
models often produced within each company.166 
 CBCT is both similar to and different from medical computed tomography (CT).  While 
they both use x-radiation in target exposure to achieve diagnostic information, the geometry of 
the beam, exposure parameters, and other aspects between the two systems are different.167  
Concordantly in medicine, the use of CT has significantly increased over the last 20 years.168  
The National Council on Radiation Protection and Measurements (NCRP) has stated that 
Americans were exposed to more than seven times as much ionizing radiation from diagnostic 
medical procedures in 2006 than they were in the early 1980s.169, 170  Much of this is directly 
attributable to the nearly ubiquitous use of CT in diagnostic medical exams.168  While the 
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radiation exposure from CBCT is usually lower than from CT, it is important to understand that 
risks of exposure still exist and that imaging principle of exposure parameters as low as 
reasonably achievable (ALARA) still applies to CBCT examination protocols.171, 172   
 With ionizing radiation, concern exists with both deterministic effects of radiation, those 
effects produced above a certain threshold dose, and stochastic effects, those effects that are 
random and probabilistic.168, 173  With CBCT dose levels, the primary concern is with stochastic 
effects.  Since limited data exists on radiation exposure and sequelae with small doses, 
extrapolation is required from higher dose evaluation.168  A fundamental problem is that 
different CBCT units have different doses for similar exam protocols, and there is no 
standardization of dose for a specific image.165  Accurate machine specific dosimetry is vital.   
 The current standard for dosimetry incorporates anthropomorphic phantoms, those 
commonly used include the radiation analog dosimetry system (RANDO) phantom (The 
Phantom Laboratory, Salem, NY), ATOM phantom (CIRS, Norfolk, VA), as well as a several 
others.165, 174-185  This standard is time-consuming, costly, and technique sensitive.186  A simple, 
inexpensive, and accurate method needs to be developed to measure dose and assess risk for a 
given scan.   
 The parallel quest in medicine to develop effective and inexpensive dosimetry has led to 
mathematical software analysis.  One such software analysis method, named Monte Carlo, has 
become prevalent.  The development actually began with the research in the 1940s on radiation 
shielding for the Manhattan Project.12  Although the specific physical parameters of the project 
were known, the solutions were eluding the researchers using traditional mathematical 
methods.  This is a broad heuristic approach, similar to the process of gambling many, many 
times (with a name like Monte Carlo, would you expect otherwise?) and recording your results, 
successful or not.  The basic premise is that these simulations sample probability distribution for 
each variable to produce thousands of possible outcomes.187  Monte Carlo simulations have 
become one of the most popular methods for modeling imaging systems, as well as being used 
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extensively for radiation dose estimation.188, 189  Since there are many different Monte Carlo 
codes, the task is to evaluate individual programs for successful and accurate analysis.12-14, 190, 191   
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OBJECTIVES 
 
 This study compared effective dose determination of four large field of view CBCT units 
(CS-9300, NewTom-3G, iCat-FLX, and Galileos Comfort Plus) using a specific Monte Carlo 
software analysis method, PCXMC 2.0 (STUK, Helsinki, Finland), developed by Tapiovaara and 
co-workers for the Finnish Radiation Nuclear Safety Authority and dosimetry using 
anthropomorphic phantoms.  The program uses a mathematically determined computational 
phantom. That information was used with the 2007 Tissue Weight factors from the ICRP to 
calculate the effective dose.   
 As accurate dosimetry is an important step in minimizing patient risk during radiologic 
examinations, accurate methods are needed to assess that risk.  Within medicine, dosimetry has 
advanced significantly, and Monte Carlo methods are widely used.  The goal of this study is to 
extend verification of Monte Carlo methods to additional dental CBCT units, and compare the 
accuracy of this specific software analysis methodology with dental dosimetry using 
anthropomorphic phantoms.   
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MATERIALS AND METHODS 
 
 This study compares simulated effective dose results from PCXMC, a user friendly, 
commercially available Monte Carlo method software application, with the effective dose results 
from previous research using dosimeters placed in tissue equivalent anthropomorphic 
phantoms.  The previous research was completed by Ludlow and co-workers evaluating the 
NewTom 3G (Cefla Dental Group, Imola, IT) using a RANDO phantom and thermoluminescent 
dosimeters (TLDs), and the Galileos Comfort Plus HD (Sirona Dental Systems, Inc. Long Island 
City, NY), the CS 9300 (Carestream Dental, Atlanta, USA) and the iCat FLX (Imaging Sciences 
International, Hatfield, PA) using ATOM phantoms and optically stimulated dosimeters 
(OSLDs).100, 101, 165, 192  Differences between the use of OSLs and TLDs, and the use of ATOM and 
RANDO phantoms were found to be less than 2% in the calculations of effective dose with ICRP 
103 values.192  Table 1Table 4 show the imaging protocols that were used on the physical 
phantoms for each machine.  These protocols were duplicated in the PCXMC software, using the 
input parameters listed in table 5. 
Table 1: NewTom 3G Included Image Protocol  
 
 
Full 30 x 30 Adult 8.1 362.2
FOV (width x height, cm) Phantom (RANDO) mAs DAP (mGy cm2)
14 
Table 2: Galileos Comfort Plus Included Image Protocols 
 
Full 15 x 15 Full child On Child 15 697
Full 15 x 15 Full teen On Child, Adult 20 915
Full 15 x 15 Full small adult On Child, Adult 25 1110
Full 15 x 15 Full child Off Child 6 252
Full 15 x 15 Full teen Off Child, Adult 8 328
Full 15 x 15 Full small adult Off Child, Adult 10 387
Maxilla 15 x 7.5 Maxilla child On Child 15 537
Maxilla 15 x 7.5 Maxilla teen On Child, Adult 20 780
Maxilla 15 x 7.5 Maxilla small adult On Child, Adult 25 958
Maxilla 15 x 7.5 Maxilla child Off Child 6 194
Maxilla 15 x 7.5 Maxilla teen Off Child, Adult 8 252
Maxilla 15 x 7.5 Maxilla small adult Off Child, Adult 10 298
Mandible 15 x 7.5 Mandible child On Child 15 391
Mandible 15 x 7.5 Mandible teen On Child, Adult 20 513
Mandible 15 x 7.5 Mandible small adult On Child, Adult 25 622
Mandible 15 x 7.5 Mandible child Off Child 6 142
Mandible 15 x 7.5 Mandible teen Off Child, Adult 8 184
Mandible 15 x 7.5 Mandible small adult Off Child, Adult 10 217
Full 15 x 15 Full large adult On Adult 30 1301
Full 15 x 15 Full large adult Off Adult 12 470
Maxilla 15 x 7.5 Maxilla large adult On Adult 30 1301
Maxilla 15 x 7.5 Maxilla large adult Off Adult 12 362
Mandible 15 x 7.5 Mandible large adult On Adult 30 729
Mandible 15 x 7.5 Mandible large adult Off Adult 12 263
mAs DAP (mGy cm2)FOV (width x height, cm) Collimation Setting Patient Setting HD Protocol Phantom (ATOM)
14
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Table 3: CS9300 Included Image Protocols 
 
8 x 8 Jaws Adult Adult 50 716
10 x 5 Jaws Maxilla Adult Adult 39 471
10 x 5 Jaws Mandible Adult Adult 39 471
17 x 13.5 Craniofacial Adult Adult 45 1585
17 x 11 Sinus Adult Adult 65 2275
17 x 11 Craniofacial Adult Fast Adult 26 898
10 x 10 Jaws Adult Adult 25 527
5 x 5 Right Posterior Maxilla Dento-alveolar Adult Fast Adult 60 366
5 x 5 Left Mid Maxilla Dento-alveolar Adult Fast Adult 60 366
5 x 5 Anterior Maxilla Dento-alveolar Adult Fast Adult 60 366
5 x 5 Left Posterior Mandible Dento-alveolar Adult Fast Adult 60 366
5 x 5 Right Mid Mandible Dento-alveolar Adult Fast Adult 60 366
5 x 5 Anterior Mandible Dento-alveolar Adult Fast Adult 60 366
5 x 5 Left Auricular Adult Fast Adult 120 873
8 x 8 Right Auricular Adult Adult 76 1078
8 x 8 TMJ Left TMJ Adult Adult 50 716
8 x 8 Jaws Adolescent Child 32 392
10 x 5 Jaws Maxilla Adolescent Child 25 258
10 x 5 Jaws Mandible Adolescent Child 25 258
17 x 13.5 Craniofacial Adolescent Child 45 1359
17 x 11 Craniofacial Adolescent Fast Child 65 1950
10 x 10 Jaws Adolescent Child 26 770
5 x 5 Right Posterior Maxilla Dento-alveolar Adolescent Fast Child 25 454
5 x 5 Left Mid Maxilla Dento-alveolar Adolescent Fast Child 60 322
5 x 5 Anterior Maxilla Dento-alveolar Adolescent Fast Child 60 322
5 x 5 Left Posterior Mandible Dento-alveolar Adolescent Fast Child 60 322
5 x 5 Right Mid Mandible Dento-alveolar Adolescent Fast Child 60 322
5 x 5 Anterior Mandible Dento-alveolar Adolescent Fast Child 60 322
5 x 5 Left Auricular Adolescent Fast Child 120 755
8 x 8 Right Auricular Adolescent Child 76 930
8 x 8 TMJ Left TMJ Adolescent Child 32 392
mAs DAP (mGy cm2)FOV (width x height, cm) Setting Patient Setting Protocol Phantom (ATOM)
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Table 4: iCat FLX Included Image Protocols  
 
8 x 8 Dental QuickScan + Adult, Child 6 40
16 x 6 Maxilla QuickScan + Adult, Child 6 49.6
16 x 6 Mandible QuickScan + Adult, Child 6 49.6
16 x 8 Both arches QuickScan + Adult, Child 6 64.9
16 x 11 Arches + TMJ QuickScan + Adult, Child 6 86.5
16 x 13 Standard Ceph QuickScan + Adult, Child 6 99.2
16 x 6 Maxilla QuickScan Adult, Child 10 168.5
8 x 8 Dental QuickScan Adult, Child 10 134.8
16 x 13 Standard Ceph QuickScan Adult, Child 10 349.4
16 x 8 Both arches QuickScan Adult, Child 10 219.6
16 x 11 Arches + TMJ QuickScan Adult, Child 10 301
16 x 6 Mandible QuickScan Adult, Child 10 163.6
8 x 8 Dental Standard Adult, Child 19 239
16 x 6 Maxilla Standard Adult, Child 19 302.9
16 x 6 Mandible Standard Adult, Child 19 291.4
16 x 8 Both arches Standard Adult, Child 19 388.9
16 x 11 Arches + Tmj Standard Adult, Child 19 543
16 x 13 Standard Ceph Standard Adult, Child 19 623.9
8 x 8 Dental High Resolution Adult 37 500.8
16 x 6 Maxilla High Resolution Adult 37 605.2
16 x 6 Mandible High Resolution Adult 37 611.6
16 x 8 Both arches High Resolution Adult 37 797.4
16 x 11 Arches + TMJ High Resolution Adult 37 1046
16 x 13 Standard Ceph High Resolution Adult 37 1257
23 x 17 EFOV Standard Adult 19 458.6
23 x 17 EFOV Enhanced Adult 37 877.6
DAP (mGy cm2)FOV (width x height, cm) Setting Protocol Phantom (ATOM) mAs
16
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Table 5: PCXMC Input Parameters 
 
 
 PCXMC uses a computational phantom with anatomical data based on the mathematical 
hermaphrodite phantoms of Cristy and Eckerman.193-195  These phantoms describe patients of 
various ages: a new-born, 1 year-old, 5 year-old, 10 year-old, 15 year-old, and adult.  The tissues 
simulated in PCXMC are soft tissue (1.04 g/cm3), lung tissue (0.296 g/cm3), and skeleton (1.40 
g/cm3, newborn 1.22 g/cm3).193  Some changes have been made to the phantoms and internal 
organs to coincide with ICRP 103 tissue weighting factors.193  Examples of these changes include 
additions of the mouth mucosa, salivary gland, extrathoracic airways, and prostate, modelled 
with guidance from ICRP Publication 89 as well as other studies.193  In addition, the program 
allows phantom size to be adjusted to match patients of any weight or height.  FOV can be freely 
adjusted relative to the patient.193 
 The program uses an Excel (Microsoft, Redmond, WA) spreadsheet for calculation of the 
total volume effective dose.  Each line within the spreadsheet represents a single pulse of the 
scan.  This means that a scan with 360 total pulses would have 360 lines in the spreadsheet.  
Within each line, the parameters of the machine and scan are entered.  Projection represents the 
Projection Projection angle relative to patient
Patient height cm
Patient weight kg
Patient age years
X-ray tube voltage kV
Machine Filtration mm Al
Additional filter mm Cu
FRD Source to reference axis distance
X-ray beam width cm, at FRD
X-ray beam height cm, at FRD
Xref FOV location coordinate, X-axis
Yref FOV location coordinate, Y-axis
Zref FOV location coordinate, Z-axis
Input dose quantity EAK,EE,DAP,EAP or MAS
Input dose value Dose value per image pulse
EAK – Air kerma, EE – Exposure, DAP – Dose Area Product 
EAP – Exposure Area Product, MAS – Current-Time Product
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numerical angle of that individual pulse.  The software angle orientation relative to the patient is 
represented in figure 1. 
  
Figure 1: PCXMC angle orientation relative to patient  
(As if looking up through the floor, so patient left is 0 degrees) 
 Considering the pathway of the source around the patient’s head, the starting angle of 
the first pulse and the ending angle of the last pulse were entered on the first and last lines 
respectively, with all the remaining intermediate pulse angles entered on the remaining lines.   
The number of scan pulses and all pulse angles were obtained from the manufacturers, 
either from the machine documentation themselves, or through direct inquiry.  Patient height, 
weight, and age similar to the phantom used in the correlating physical scan were entered.  
PCXMC settings for an adult 30 year-old are 178.6 cm height and 73.2 kg weight, and the child 
setting for a 10 year old is 139.8 cm height and 32.4 kg weight.   This is similar in external 
dimensions to the ATOM adult phantom (model 701-HN, CIRS, Norfolk, VA) which represents a 
30 year old human of 173 cm height and 73 kg weight, and the ATOM child (model 706-HN, 
CIRS, Norfolk, VA), which represents a 10 year-old human of 140 cm and 32 kg.  Machine 
filtration was entered in from the specific scanner product documentation.  The FRD represents 
the distance between the x-ray source and the rotational reference point axis of the scan.  This 
distance is found from product documentation or directly from the manufacturer.  The x-ray 
beam width and height are calculated using the individual scan collimations, which create 
specific x-ray beam field dimensions at the receptor.  The scan collimations are obtained from 
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product documentation or directly from the manufacturer.  The width and height of the x-ray 
beam field at the reference axis are calculated from the x-ray beam field at the receptor using 
trigonometry.  Given the dimensions of the field at the receptor, the x-ray beam may be 
considered a square pyramid, with the source as the apex.  The height of the pyramid is the 
source to receptor distance, obtained either from machine documentation or directly from the 
manufacturer.  As the dimensions of the base and height of the pyramid are known, the field of 
view at the reference axis can be calculated.   
 The x-ray tube voltage was entered from the parameters of the specific scan.   The x, y, 
and z references are the coordinates of the center of the rectangular scan field at the reference 
axis.  PCXMC has a simulated scout window, shown in figure 2, which allows visual placement of 
the scan relative to the patient.  Each simulated scan is situated to replicate phantom scan 
placement.  The input dose quantity chosen for this research was mAs and dose area product 
(DAP).  Each machine provides both mAs and DAP for each scan protocol.  For each scan, these 
are divided by the number of scan pulses for that scan, and entered under the category “input 
dose value,”  with the mAs per pulse on each line of the mAs scan, and the DAP per pulse on 
each line of the DAP scan.  For each phantom scan protocol, one simulated scan was run using 
the mAs input value, and then another simulated scan using the DAP input value.   
 
Figure 2: PCXMC Positioning and scout window 
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 For the purpose of the mathematical evaluation, the program considers that the x-ray 
photons are emitted from a point source and then interact within the parameters specified in the 
scan (x-ray FOV size, patient reference axis, pulse angle, etc.).  Pseudo-random numbers are 
generated to simulate photon direction, interaction distance, type of interacting atom, 
interaction type with that atom, scatter angle, and energy loss.  These photons are then followed 
in their interactions in the phantom using the probability of types of scatter or photoelectric 
absorption.193  The process of interactions is compiled to create a “photon history.”  Many 
independent photon histories are created, which then are used to estimate the energy deposited 
in the simulated organs of the phantom.193   
 From this information, the program calculates the effective dose using both ICRP 103 
and 60 values.  The sum of each line effective dose is taken, representing the effective dose of the 
entire scan.  For this study, only ICRP 103 values were evaluated.  PCXMC 2.0 was run on a 
laptop computer (Lenovo, Morrisville, NC and Beijing, China) using Windows 7 (Microsoft, 
Redmond, WA).   
 Dosimetry values were calculated using these parameters and compared with phantom 
dosimetry results.  The null hypothesis, that there is no statistically significant difference 
between the dosimetry values of the anthropomorphic phantom and the calculated values of the 
PCXMC software, was tested.   
 Similar to previous studies, initial evaluation consisted of simple percent difference 
relative to the phantom measured dose.196  The results (organ equivalent doses and total 
effective doses) were then categorized into a binary variable: positive if the estimated results 
were within ±20% of the phantom, and negative for everything else.  All statistics were run using 
SPSS statistical software (IBM, Armonk, New York, USA).  A chi-square test was performed 
comparing mAs versus DAP input variables on effective dose.  Logistic regression was 
performed using the following variables relative to the binary effective dose: machine used, 
phantom used (adult or child), FOV location, FOV volume size, and phantom measured dose.  
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Due to the unitary data from the NewTom 3G, it was excluded from machine specific, but not 
global, comparisons.  To evaluate equivalent dose among the different organs, another chi-
square was completed.  
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RESULTS 
 
 The percent difference of the PCXMC estimated doses relative to the phantom doses are 
given in figure 3-figure 6.   
 
Figure 3: NewTom 3G PCXMC effective dose estimates relative to phantom 
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Figure 4: Sirona Galileos Comfort Plus PCXMC effective dose estimates relative to phantom 
 
2
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Figure 5: CS9300 PCXMC effective dose estimates relative to phantom 
 
2
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Figure 6: iCat FLX PCXMC effective dose estimates relative to phantom 
2
5
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 Using mAs as the input variable resulted in simulated effective doses at or below the 
±20% target threshold 48% of the time.  Increasing the threshold to ±30% would result in 60% 
success, and to ±50%, 77% success.  Using DAP as the input variable resulted in simulated 
effective doses at or below the ±20% threshold 57% of the time.  Increasing that threshold to 
±30% would result in 70% success, and to ±50%, 82% success.  Differences were as much as 
300% on the CS9300 for certain small FOVs.  Even though there are visual percent differences 
between using mAs or DAP, the chi-square analysis showed there was not a significant 
association between input variable (mAs or DAP) and whether or not PCXMC predicted dose 
was within ±20% of the phantom measured effective dose χ2 (1)=1.791, p=.114.   
 The logistic regression results showed that the only consistently significant finding was 
FOV location.  Those protocols strictly in the maxilla and above were less likely to stay below the 
target threshold, and those that encompassed both maxilla and mandible were more likely to 
stay below the target threshold.  When mAs was used as the input variable, effective doses in 
larger volumes were slightly less likely to be below the target threshold.  When DAP was used as 
the input variable, effective doses in the adult phantom were more likely to be below the target 
threshold.  The results are shown in figure 7 and Figure 8.   
 
Figure 7: Logistic Regression with mAs as the input variable.  Variables examined included machine used, 
phantom used (adult or child), FOV location, FOV volume size, and phantom measured dose 
Parameter DF Estimate SE
Wald Chi-
Square
Pr > 
ChiSq
Machine CS9300 1 -0.1475 0.3429 0.1851 0.667
Machine iCat FLX 1 0.3782 0.4128 0.8396 0.3595
Phantom Used Adult 1 -0.5252 0.4698 1.2496 0.2636
Dose 1 -0.00338 0.00493 0.4701 0.493
FOV Location Full 1 2.0433 0.4315 22.4212 <.0001
FOV Location Maxilla 1 -1.5152 0.3899 15.1014 0.0001
FOV Volume (cm3) 1 -0.00089 0.00035 6.304 0.012
Analysis of Maximum Likelihood Estimates (mAs)
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Figure 8: Logistic Regression with DAP as the input variable.  Variables examined included machine used, 
phantom used (adult or child), FOV location, FOV volume size, and phantom measured dose. 
 
The percentage of the software organ equivalent dose estimates that were within ±20% of the 
phantom measured doses are given in figure 9.  
 
Figure 9: Percentage of PCXMC organ dose estimates within ±20% of phantom, with DAP or mAs as input 
variable. 
 
Parameter DF Estimate SE
Wald Chi-
Square
Pr > 
ChiSq
Machine CS9300 1 -0.6237 0.3343 3.4804 0.0621
Machine iCat FLX 1 -0.0098 0.3643 0.0007 0.9785
Phantom Used Adult 1 1.4437 0.4695 9.4547 0.0021
Dose 1 0.00597 0.00548 1.1836 0.2766
FOV Location Full 1 0.9107 0.3621 6.3241 0.0119
FOV Location Maxilla 1 -1.2947 0.3583 13.0584 0.0003
FOV Volume (cm3) 1 -0.00027 0.000222 1.4429 0.2297
Analysis of Maximum Likelihood Estimates (DAP)
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 In evaluating equivalent dose on the organs, the mucosa, salivary glands, and airway had 
the most estimates within the threshold using both mAs and DAP.  Lymph nodes had none in 
both.   
 The chi-square analysis on the equivalent doses of all the organs shows that when using 
mAs as the input variable, there is a significant but only moderate association between the organ 
and whether the dose was within the phantom dose threshold (χ2 (9)=76.945, p<.001, Cramer’s 
V= .262).  Using DAP as the input variable, the association was slightly stronger (χ2 
(9)=168.714, p<.001, Cramer’s V= .388).  Figure 10 and figure 11 show the standardized 
residuals.  Positive and negative values represents greater than or less than expected counts, and 
the number value represents the significance.  All other organs were not significant.  (See 
Appendix 1 and 2) 
 
Figure 10: Chi-square standardized residuals, with mAs as input value 
 
Figure 11: Chi-square standardized residuals, with DAP as input value 
Organ Std. Residual
Salivary 4.2
Mucosa 3.6
Thyroid -3.2
Esophagus -3.9
Organ Std. Residual
Mucosa 7.3
Airway 4.6
Salivary 4.3
Skeleton -2.1
Brain -2.1
Esophagus -2.5
Thyroid -3.7
Skin -4.1
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DISCUSSION 
 
 In evaluating of the significance of the FOV location, previous research has 
demonstrated that when organs are partially within the x-ray field, doses can drastically differ 
between phantoms.197  While this doesn’t explain why mandibular FOVs were not significantly 
different, it does logically follow that as more organs are partially within the scan, the more 
variance between phantoms is encountered.   
 However, this does not explain the only significant finding relating to FOV size.  When 
using mAs as the input variable, larger FOVs were slightly less likely of being within 20% of the 
phantom measured effective dose.  Logically, it follows that a smaller FOV would have more 
organs partially within the scan, and accordingly, greater variability.  Other than the fact that the 
likelihood ratio is so small (-0.00089) that it may be statistically, but not practically significant, 
this finding cannot be explained at this time.   
 The variance in adult versus child phantom when using DAP is consistent with previous 
research, that found significant changes in effective dose without any change in DAP.198  
Additionally, studies have shown vast differences in conversion factors when attempting to 
equate DAP with effective dose.165, 199  In the protocols that scanned both adult and child 
phantoms, DAP did not change between the two.  Child phantom organ positioning may have an 
even greater effect on effective dose deviations in this instance, as more organs, particularly the 
thyroid, are included or proximal to the beam.192  Differences in organ position can have 
significant effects on organ and equivalent dose.200   
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Limitations 
 Initial concerns were regarding the machine specific FOV geometry, since PCXMC 
calculates the scan as a cylinder.  Two of the machines evaluated, the NewTom 3G and Galileos, 
have spherical FOVs, while the CS9300 and iCat FLX have a cylindrical FOVs.  However, no 
significant difference was found between the machines themselves.   
 Additionally, as PCXMC allows for FOV placement in all three planes (X, Y, and Z) the 
positioning scan, particularly with smaller protocols, will always be a potential source of error.  
While a scout window is present within PCXMC, positioning still requires human judgment.  To 
test this, software scans were run with several cm differences in positioning.  Estimated effective 
dose from the software varied less than 5% with different positions, unless the exam bordered 
the thyroid.  Greater inclusion of the thyroid within the scan by moving the target inferiorly 
increased the estimated effective dose upwards of 15%, with dramatic increases in equivalent 
dose to the organ itself.  However, the potential variation is still present, and is illustrated in 
several 5x5 FOV protocols in the CS9300, which demonstrated some of the highest variation in 
this study, with differences ranging from 3% to above 200 and 300% difference from the 
phantom.  PCXMC overestimated doses in 13 out of 14 instances.  In this machine specific subset 
of imaging protocols, there was no consistency on location relative to percent difference 
(posterior/anterior FOV, or maxillary/mandibular FOV) 
 Another significant potential source of error is the choice of the phantom itself.  There 
are a few different types of computational phantoms.  The phantom used in PCXMC is a 
hermaphroditic, mathematical computational phantom, often called ‘stylized,’ ‘mathematical’ or 
‘MIRD-type,’ since they were introduced by the Medical Internal Radiation Dose Committee 
(MIRD).201  The internal organ structure and exterior tissue are described by three-dimensional 
surface equations.202  This mathematical polyhedral method of representing organs can be 
considered simplistic compared to the complex anatomy of the human body, and as such, can 
introduce the potential for error in dose estimations.202  Another group of computational 
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phantoms are “voxel” or “tomographic” phantoms.  These phantoms use magnetic resonance 
(MR) or CT image information to construct organ and body structure.202  A third recent type of 
computational phantom has been developed – called “hybrid” or “boundary representation” 
(BREP) phantoms.184, 203 These phantoms have the benefit of being easily deformable – which 
allows the alteration to fit different organ shapes or different body types.  These may be 
constructed with a polygonal mesh – a set of faces that determine the polyhedral shape of 
organs and other structures.  These newer phantoms allow for simulation of particularly 
complex anatomies.184   
 The computational phantoms with more realistic anatomy have been compared to the 
initial stylized phantoms.197, 203-207  Exposure levels in organs between certain phantoms (and 
classes of phantoms) can vary significantly, and relate to organ shape and distribution.202, 207  
Effective dose can depend strongly on the choice of phantom, organ positions, and field size and 
position.200  The phantom used in PCXMC includes soft tissue, lung tissue, and skeleton.  The 
ATOM phantom includes soft tissue, spinal cord, spinal disks, lung, brain, and sinus, and the 
RANDO phantom includes soft tissue, lungs, and natural human skeletons.176, 177  Although 
phantom tissue attenuation factors aim to follow ICRP recommendations, there are natural 
variations between human bone and polymers, as well as inherent differences between 
systems.177, 193  Even when comparing different phantoms of the same type (e.g. voxel phantoms 
with voxel phantoms), differences in effective dose have been found to range up to nearly 
50%.206  Of note is when there is inability to alter the orientation of the phantom head within the 
scan to more appropriately model patient head positioning.  Since positioning within the scan 
has been shown to make a significant difference on organ and effective dose,94, 96, 99, 198 this 
results in the fact that phantoms intended for general dosimetry may ultimately be limited and 
present with inherent variance when used in dental CBCT application.   
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PCXMC Previous Validation Studies 
 Studies comparing PCXMC with other Monte Carlo programs and phantoms have shown 
varying levels of agreement.139, 197  In evaluating PCXMC with MCNP, a Monte Carlo program 
from the Los Alamos National Laboratory (LANL) Schultz and co-workers found that while the 
PCXMC estimated individual organ doses during pediatric cardiology procedures sometimes 
varied considerably from the MCNP values, effective dose had more reasonable agreement.139  
Since the effective doses evaluated were in mSv, the acceptable margin of error included 
differences of up to nearly 800 µSv.139  
 In comparing PCXMC with a voxel phantom and MCNPX (LANL, Los Alamos, NM), 
Smans and co-workers found increased differences in mean organ dose between phantoms 
when organs were partially within the x-ray field, as much as 700%.197  Even when the different 
phantoms underwent total body irradiation, differences in mean organ doses between the 
phantoms ranged from 1%-96%.197   
 Previous studies have shown similar range of agreement with PCXMC effective dose 
estimations and other physical dose measurements.139, 146, 193, 200, 208, 209  Schmidt and co-workers 
found that a comparison of PCXMC estimates with a list of doses from a selection of common 
cardiac projections for 1 Gy entrance air kerma was within 10-20%.200  Effective doses in this 
comparison ranged from approximately 5-25mSv.  The accepted percent variance of 20% 
difference of 20mSv correlates to 4 mSv, or 4,000 µSv, which is a 1300% difference from the 
maximum phantom calculated effective dose (less than 0.3 mSv, or 300 µSv) of the machines 
evaluated in this study.  Khelassi-Toutaoui and co-workers compared PCXMC with PREPARE 
(ORNL, Oak Ridge, TN), another MC program against TLDs in a RANDO phantom during 
simulated lung exposures.  The authors found that phantom measured doses correlated better 
with the PCXMC values than the PREPARE values.  PCXMC organ dose values were within 28% 
in 60% of the samples.209   
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 Another study by Helmrot and co-workers found that software estimated absorbed doses 
agreed within ±50% of measured absorbed doses to the uterus.208  The difference between 
PCXMC estimates and measured absorbed dose in this study was commonly within the range of 
0.1-0.2 mGy (100-200 µGy) and varied as much as 5mGy.208  Wood and co-workers evaluated 
the CBCT dose associated with a Varian on-board-imager CBCT (OBI, Varian Medical Systems, 
Palo Alto, CA) against RANDO phantom TLDs.  The authors found that the majority of software 
estimated organ doses were within 20%.146   As the doses were in mGy, the smallest number 
difference was 0.3 mGy, or 300 µGy.  Overall, even though PCXMC was shown to have 
reasonable agreement with the comparison phantoms, Monte Carlo programs, and other dose 
measurements, the acceptable difference margin in those studies often exceeded the largest 
doses evaluated within this present study.   
 
Organ doses 
 The evaluation of PCXMC organ dose estimations should be approached with a  caveat – 
as it is explicitly stated within software documentation that they are only strictly valid for 
phantoms used in the calculation.193  Statistical analysis on the organs shows that while the 
organ does have a significant effect on being within the threshold dose, the association between 
the two is only low to medium in strength.  Cramer’s V, a measure of the association between 
organ and being within threshold dose, was .262 and .388 for mAs and DAP respectively.  One 
key finding is that with both mAs and DAP, the thyroid had significantly less than expected hits 
within the phantom dose threshold (both p< .001, see Appendix 1 and 2).  This is important as 
the thyroid, while on the periphery of most scans, contributes significantly to effective dose 
when it is scan adjacent.  Specifically regarding the lymph nodes, PCXMC does not model the 
nodes themselves, but compiles a dose estimate from doses in surrogate organs, explained in 
figure 12.193  This would explain the zero success rate – as the majority of organs within the 
compilation are far from the primary beam.  In contrast, previous ATOM phantom dental CBCT 
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dosimetry accounts for lymph nodes by averaging from dosimeters near anatomical head and 
neck lymph node locations.  Additionally, precision of the dose estimate may be low if the dose 
to the organ is low.193  Common doses in dental CBCT are 10-1000 times less than those 
protocols used in studies cited previously.  This primarily explains the low global success rate in 
organ dose estimation.  This reiterates an important issue – since effective dose is compiled 
from organ doses, differences between phantoms can lead to significant variations in dose.   
 
Figure 12: PCXMC lymph node dose calculation 
  
Dental CBCT Dose concerns: Are they worth discussing? 
 Since the dose levels of dental CBCT are generally low relative to medical diagnostic 
radiology protocols, are they even worth discussing?  While certain individuals have stated that 
additional low level radiation exposure is beneficial to health,210-213 reviews of any published 
literature has not been strongly supportive.214, 215   Even among professional bodies there is 
continual discussion of dose levels and related risks.  While in 2011, the American Association of 
Physicists in Medicine released a policy statement declaring that the “risks of medical imaging at 
effective doses below 50 mSv (50,000 µSv)…may be nonexistent”,216 other studies have found 
increased risks of leukemia and brain cancers at similar doses,217, 218 and NCRP report #116 
recommended that a negligible annual individual dose be considered as low as 0.01 mSv (10 
µSv).219  Individual dental CBCT scans are regularly above the NCRP recommended level.  Even 
though the risk is extrapolated from higher doses and is small for an individual, applying this to 
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a population of patients results in a public health concern that cannot be deemed 
insignificant.165  Thus, dental CBCT doses ARE worth discussing.   
 
Future Directions 
 The idea of Monte Carlo analysis is to create a model that very closely simulates the real 
system, then calculate interactions.188  As anthropomorphic phantoms have been shown to 
reliably measure effective dose with dental CBCT,220 MC programs must act similarly in order to 
be a precise and accurate substitution.  The utilization of programs with newer phantoms that: 
1) more closely model human anatomy and 2) allow for realistic adjustment to match patient 
populations and 3) allow positioning to match dental patient imaging protocols may ultimately 
become the future of dental dosimetry.   
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CONCLUSIONS 
 
 PCXMC is not currently a generally acceptable substitution for the current standard of 
dental CBCT phantom dosimetry.  A ±50% threshold relative to current phantom dosimetry is 
required for the program to be successful 80% of the time.  While the software calculations are 
simpler to perform than anthropomorphic phantom dosimetry, simplicity is not an acceptable 
tradeoff for this level of imprecision in most applications. 
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APPENDIX 1: MAS INPUT VARIABLE ORGAN CHI-SQUARE ANALYSIS 
Organs Coded * mAs Hit Threshold? Crosstabulation   
  
mAs Hit Threshold? 
Total 
  
NO YES   
Organs Coded Marrow Count 89 23 112   
Expected 
Count 
89.8 22.2 112.0 
  
% within 
Organs Coded 
79.5% 20.5% 100.0% 
  
% within mAs 
Hit Threshold? 9.9% 10.4% 10.0% 
  
% of Total 7.9% 2.1% 10.0%   
Std. Residual -.1 .2     
Thyroid Count 105 7 112   
Expected 
Count 
89.8 22.2 112.0 
  
% within 
Organs Coded 
93.8% 6.3% 100.0% 
  
% within mAs 
Hit Threshold? 11.7% 3.2% 10.0% 
  
% of Total 9.4% .6% 10.0%   
Std. Residual 1.6 -3.2     
Esophagus Count 108 4 112   
Expected 
Count 
89.8 22.2 112.0 
  
% within 
Organs Coded 
96.4% 3.6% 100.0% 
  
% within mAs 
Hit Threshold? 12.0% 1.8% 10.0% 
  
% of Total 9.6% .4% 10.0%   
Std. Residual 1.9 -3.9     
Skin Count 94 18 112   
Expected 
Count 
89.8 22.2 112.0 
  
% within 
Organs Coded 
83.9% 16.1% 100.0% 
  
% within mAs 
Hit Threshold? 10.5% 8.1% 10.0% 
  
% of Total 8.4% 1.6% 10.0%   
Std. Residual .4 -.9     
Skeleton Count 91 21 112   
Expected 
Count 
89.8 22.2 112.0 
  
% within 
Organs Coded 
81.3% 18.8% 100.0% 
  
% within mAs 
Hit Threshold? 10.1% 9.5% 10.0% 
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% of Total 8.1% 1.9% 10.0%   
Std. Residual .1 -.3     
Salivary Count 70 42 112   
Expected 
Count 
89.8 22.2 112.0 
  
% within 
Organs Coded 
62.5% 37.5% 100.0% 
  
% within mAs 
Hit Threshold? 7.8% 18.9% 10.0% 
  
% of Total 6.3% 3.8% 10.0%   
Std. Residual -2.1 4.2     
Brain Count 97 15 112   
Expected 
Count 
89.8 22.2 112.0 
  
% within 
Organs Coded 
86.6% 13.4% 100.0% 
  
% within mAs 
Hit Threshold? 10.8% 6.8% 10.0% 
  
% of Total 8.7% 1.3% 10.0%   
Std. Residual .8 -1.5     
Airway Count 82 30 112   
Expected 
Count 
89.8 22.2 112.0 
  
% within 
Organs Coded 
73.2% 26.8% 100.0% 
  
% within mAs 
Hit Threshold? 9.1% 13.5% 10.0% 
  
% of Total 7.3% 2.7% 10.0%   
Std. Residual -.8 1.7     
Muscle Count 89 23 112   
Expected 
Count 
89.8 22.2 112.0 
  
% within 
Organs Coded 
79.5% 20.5% 100.0% 
  
% within mAs 
Hit Threshold? 9.9% 10.4% 10.0% 
  
% of Total 7.9% 2.1% 10.0%   
Std. Residual -.1 .2     
Mucosa Count 73 39 112   
Expected 
Count 
89.8 22.2 112.0 
  
% within 
Organs Coded 
65.2% 34.8% 100.0% 
  
% within mAs 
Hit Threshold? 8.1% 17.6% 10.0% 
  
% of Total 6.5% 3.5% 10.0%   
Std. Residual -1.8 3.6     
Total Count 898 222 1120   
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Expected 
Count 
898.0 222.0 1120.0 
  
% within 
Organs Coded 
80.2% 19.8% 100.0% 
  
% within mAs 
Hit Threshold? 100.0% 100.0% 100.0% 
  
% of Total 80.2% 19.8% 100.0%   
        
Chi-Square Tests  
  Value df 
Asymp. 
Sig. (2-
sided) 
Exact Sig. 
(2-sided) 
Exact Sig. 
(1-sided) 
Point 
Probability  
Pearson Chi-
Square 
76.945a 9 .000 .000     
 
Likelihood 
Ratio 
82.788 9 .000 .b     
 
Fisher's Exact 
Test 
.b     .b     
 
Linear-by-
Linear 
Association 
26.943c 1 .000 .000 .000 .000 
 
N of Valid 
Cases 
1120           
 
a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 22.20. 
 
b. Cannot be computed because there is insufficient memory. 
 
c. The standardized statistic is 5.191. 
 
        
Directional Measures 
  Value 
Asymp. 
Std. 
Errora 
Approx. 
Tb 
Approx. 
Sig. 
Exact 
Sig. 
Nominal by 
Nominal 
Lambda Symmetric .031 .013 2.353 .019   
Organs Coded 
Dependent .038 .016 2.353 .019   
mAs Hit 
Threshold? 
Dependent 
0.000 0.000 .c .c   
Goodman and 
Kruskal tau 
Organs Coded 
Dependent .008 .002   .000
d .000 
mAs Hit 
Threshold? 
Dependent 
.069 .014   .000d .e 
a. Not assuming the null hypothesis. 
b. Using the asymptotic standard error assuming the null hypothesis. 
c. Cannot be computed because the asymptotic standard error equals zero. 
d. Based on chi-square approximation 
e. Cannot be computed because there is insufficient memory. 
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Symmetric Measures    
  Value 
Approx. 
Sig. Exact Sig.    
Nominal by 
Nominal 
Phi .262 .000 .000    
Cramer's V .262 .000 .000    
Contingency 
Coefficient 
.254 .000 .000 
   
N of Valid Cases 1120        
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APPENDIX 2: DAP INPUT VARIABLE ORGAN CHI-SQUARE ANALYSIS 
Organs Coded * DAP Hit Threshold? Crosstabulation   
  
DAP Hit Threshold? 
Total 
  
NO YES   
Organs Coded Marrow Count 96 16 112   
Expected 
Count 
92.9 19.1 112.0 
  
% within 
Organs Coded 
85.7% 14.3% 100.0% 
  
% within DAP 
Hit Threshold? 10.3% 8.4% 10.0% 
  
% of Total 8.6% 1.4% 10.0%   
Std. Residual .3 -.7     
Thyroid Count 109 3 112   
Expected 
Count 
92.9 19.1 112.0 
  
% within 
Organs Coded 
97.3% 2.7% 100.0% 
  
% within DAP 
Hit Threshold? 11.7% 1.6% 10.0% 
  
% of Total 9.7% .3% 10.0%   
Std. Residual 1.7 -3.7     
Esophagus Count 104 8 112   
Expected 
Count 
92.9 19.1 112.0 
  
% within 
Organs Coded 
92.9% 7.1% 100.0% 
  
% within DAP 
Hit Threshold? 11.2% 4.2% 10.0% 
  
% of Total 9.3% .7% 10.0%   
Std. Residual 1.2 -2.5     
Skin Count 111 1 112   
Expected 
Count 
92.9 19.1 112.0 
  
% within 
Organs Coded 
99.1% .9% 100.0% 
  
% within DAP 
Hit Threshold? 11.9% .5% 10.0% 
  
% of Total 9.9% .1% 10.0%   
Std. Residual 1.9 -4.1     
Skeleton Count 102 10 112   
Expected 
Count 
92.9 19.1 112.0 
  
% within 
Organs Coded 
91.1% 8.9% 100.0% 
  
% within DAP 
Hit Threshold? 11.0% 5.2% 10.0% 
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% of Total 9.1% .9% 10.0%   
Std. Residual .9 -2.1     
Salivary Count 74 38 112   
Expected 
Count 
92.9 19.1 112.0 
  
% within 
Organs Coded 
66.1% 33.9% 100.0% 
  
% within DAP 
Hit Threshold? 8.0% 19.9% 10.0% 
  
% of Total 6.6% 3.4% 10.0%   
Std. Residual -2.0 4.3     
Brain Count 102 10 112   
Expected 
Count 
92.9 19.1 112.0 
  
% within 
Organs Coded 
91.1% 8.9% 100.0% 
  
% within DAP 
Hit Threshold? 11.0% 5.2% 10.0% 
  
% of Total 9.1% .9% 10.0%   
Std. Residual .9 -2.1     
Airway Count 73 39 112   
Expected 
Count 
92.9 19.1 112.0 
  
% within 
Organs Coded 
65.2% 34.8% 100.0% 
  
% within DAP 
Hit Threshold? 7.9% 20.4% 10.0% 
  
% of Total 6.5% 3.5% 10.0%   
Std. Residual -2.1 4.6     
Muscle Count 97 15 112   
Expected 
Count 
92.9 19.1 112.0 
  
% within 
Organs Coded 
86.6% 13.4% 100.0% 
  
% within DAP 
Hit Threshold? 10.4% 7.9% 10.0% 
  
% of Total 8.7% 1.3% 10.0%   
Std. Residual .4 -.9     
Mucosa Count 61 51 112   
Expected 
Count 
92.9 19.1 112.0 
  
% within 
Organs Coded 
54.5% 45.5% 100.0% 
  
% within DAP 
Hit Threshold? 6.6% 26.7% 10.0% 
  
% of Total 5.4% 4.6% 10.0%   
Std. Residual -3.3 7.3     
Total Count 929 191 1120   
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Expected 
Count 
929.0 191.0 1120.0 
  
% within 
Organs Coded 
82.9% 17.1% 100.0% 
  
% within DAP 
Hit Threshold? 100.0% 100.0% 100.0% 
  
% of Total 82.9% 17.1% 100.0%   
        
Chi-Square Tests  
  Value df 
Asymp. 
Sig. (2-
sided) 
Exact Sig. 
(2-sided) 
Exact Sig. 
(1-sided) 
Point 
Probability  
Pearson Chi-
Square 
168.714a 9 .000 .000     
 
Likelihood 
Ratio 
168.875 9 .000 .b     
 
Fisher's Exact 
Test 
.b     .b     
 
Linear-by-
Linear 
Association 
70.876c 1 .000 .000 .000 .000 
 
N of Valid 
Cases 
1120           
 
a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 19.10. 
 
b. Cannot be computed because there is insufficient memory. 
 
c. The standardized statistic is 8.419. 
 
        
Directional Measures 
  Value 
Asymp. 
Std. 
Errora 
Approx. 
Tb 
Approx. 
Sig. 
Exact 
Sig. 
Nominal by 
Nominal 
Lambda Symmetric .042 .013 3.033 .002   
Organs Coded 
Dependent .050 .016 3.033 .002   
DAP Hit 
Threshold? 
Dependent 
0.000 0.000 .c .c   
Goodman and 
Kruskal tau 
Organs Coded 
Dependent .017 .002   .000
d .000 
DAP Hit 
Threshold? 
Dependent 
.151 .022   .000d .e 
a. Not assuming the null hypothesis. 
b. Using the asymptotic standard error assuming the null hypothesis. 
c. Cannot be computed because the asymptotic standard error equals zero. 
d. Based on chi-square approximation 
e. Cannot be computed because there is insufficient memory. 
        
44 
Symmetric Measures    
  Value 
Approx. 
Sig. Exact Sig.    
Nominal by 
Nominal 
Phi .388 .000 .000    
Cramer's V .388 .000 .000    
Contingency 
Coefficient 
.362 .000 .000 
   
N of Valid Cases 1120        
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